Hotchkis & Wiley Capital Management LLC grew its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 7.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 73,842 shares of the company’s stock after purchasing an additional 4,880 shares during the quarter. Hotchkis & Wiley Capital Management LLC’s holdings in USANA Health Sciences were worth $6,808,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of USNA. Invesco Ltd. lifted its stake in shares of USANA Health Sciences by 155.0% during the 2nd quarter. Invesco Ltd. now owns 164,515 shares of the company’s stock worth $16,851,000 after purchasing an additional 99,993 shares during the period. Pzena Investment Management LLC purchased a new position in shares of USANA Health Sciences in the 3rd quarter worth $8,824,000. Nordea Investment Management AB raised its position in shares of USANA Health Sciences by 97.6% in the 3rd quarter. Nordea Investment Management AB now owns 157,578 shares of the company’s stock worth $14,438,000 after buying an additional 77,851 shares during the period. JPMorgan Chase & Co. raised its position in shares of USANA Health Sciences by 91.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 88,971 shares of the company’s stock worth $9,113,000 after buying an additional 42,457 shares during the period. Finally, Bridgewater Associates LP purchased a new position in shares of USANA Health Sciences in the 2nd quarter worth $3,742,000. 54.82% of the stock is currently owned by institutional investors.

NYSE:USNA opened at $95.55 on Monday. The business’s 50-day moving average is $100.33 and its two-hundred day moving average is $98.08. USANA Health Sciences, Inc. has a 12 month low of $80.00 and a 12 month high of $107.85. The firm has a market capitalization of $1.86 billion, a PE ratio of 14.59 and a beta of 0.85.

In related news, insider David Mulham Mulham sold 1,277 shares of USANA Health Sciences stock in a transaction dated Wednesday, November 3rd. The stock was sold at an average price of $99.63, for a total value of $127,227.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel A. Macuga sold 368 shares of USANA Health Sciences stock in a transaction dated Wednesday, December 8th. The stock was sold at an average price of $100.86, for a total value of $37,116.48. The disclosure for this sale can be found here. Insiders have sold 9,360 shares of company stock valued at $953,060 over the last 90 days. Insiders own 0.21% of the company’s stock.

Several research analysts recently weighed in on the company. Zacks Investment Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 29th. Tigress Financial reaffirmed a “buy” rating and issued a $122.00 target price on shares of USANA Health Sciences in a research report on Friday, October 8th.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

See Also: Special Purpose Acquisition Company (SPAC) – What You Need to Know

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).